Risk Profiles of New Users of Oral Anticoagulants Between 2011 and 2019 in Germany

References

• Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217–221. doi:10.1177/1747493019897870
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi:10.1016/S0140-6736(13)62343-0
   PubMed Web of Science ®Google Scholar
• Friberg L, Oldgren J. Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. Open Heart. 2017;4(2):e000682. doi:10.1136/openhrt-2017-000682
   PubMedGoogle Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. doi:10.1056/NEJMoa1009638
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. doi:10.1056/NEJMoa1107039
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104. doi:10.1056/NEJMoa1310907
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa0905561
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962. doi:10.1093/eurheartj/ehw210
   PubMed Web of Science ®Google Scholar
• Ludwig W-D, Mühlbauer B, Seifert R. Antithrombotika und Antihämorrhagika [Antithrombotics and antihemorrhagics]. In: Arzneiverordnungs-Report 2021. Springer; 2021:299–326. German.
   Google Scholar
• Menichelli D, Del Sole F, Di Rocco A, et al. Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients. Eur Heart J Cardiovasc Pharmacother. 2021;7(FI1):f11–f19. doi:10.1093/ehjcvp/pvab002
   PubMedGoogle Scholar
• Zhu W, Ye Z, Chen S, et al. Comparative effectiveness and safety of non–vitamin K antagonist oral anticoagulants in atrial fibrillation patients. Stroke. 2021;52(4):1225–1233. doi:10.1161/STROKEAHA.120.031007
   PubMed Web of Science ®Google Scholar
• Li G, Lip GY, Holbrook A, et al. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Eur J Epidemiol. 2019;34:173–190. doi:10.1007/s10654-018-0415-7
   PubMed Web of Science ®Google Scholar
• Laliberte F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2014;30(7):1317–1325. doi:10.1185/03007995.2014.907140
   PubMed Web of Science ®Google Scholar
• Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GYH. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189. doi:10.1136/bmj.i3189
   PubMed Web of Science ®Google Scholar
• Paschke LM, Klimke K, Altiner A, von Stillfried D, Schulz M. Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study. BMC Med. 2020;18(1):1–13. doi:10.1186/s12916-020-01695-7
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Basic E, Hohmann C, Nabauer M. Effectiveness and safety of non–vitamin K oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation. Thromb Haemost. 2018;118(03):526–538. doi:10.1160/TH17-10-0733
   PubMedGoogle Scholar
• Hohnloser SH, Basic E, Nabauer M. Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. Clin Res Cardiol. 2017;106(8):618–628. doi:10.1007/s00392-017-1098-x
   PubMed Web of Science ®Google Scholar
• Jaksa A, Gibbs L, Kent S, et al. Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study. BMJ Open. 2022;12(10):e064662. doi:10.1136/bmjopen-2022-064662
   PubMed Web of Science ®Google Scholar
• Haug U, Schink T. German pharmacoepidemiological research database (GePaRD). In: Databases for Pharmacoepidemiological Research. Springer; 2021:119–124.
   Google Scholar
• Komen JJ, Pottegård A, Mantel-Teeuwisse AK, et al. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. EP Europace. 2021;23(11):1722–1730. doi:10.1093/europace/euab091
   PubMed Web of Science ®Google Scholar
• Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41(12):2731–2738. doi:10.1161/STROKEAHA.110.590257
   PubMed Web of Science ®Google Scholar
• Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol. 2011;57(2):173–180. doi:10.1016/j.jacc.2010.09.024
   PubMed Web of Science ®Google Scholar
• Halvorsen S, Johnsen SP, Madsen M, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study. Eur Heart J Qual Care Clin Outcomes. 2022;8(5):577–587. doi:10.1093/ehjqcco/qcab048
   PubMed Web of Science ®Google Scholar
• Gupta K, Trocio J, Keshishian A, et al. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population. BMC Cardiovasc Disord. 2019;19(1):1–10. doi:10.1186/s12872-019-1116-1
   PubMedGoogle Scholar
• Voss A, Smits E, Swart KM, et al. Time trends in patient characteristics of new rivaroxaban users with atrial fibrillation in Germany and the Netherlands. Drugs Real World Outcomes. 2023. doi:10.1007/s40801-022-00350-2
   PubMedGoogle Scholar
• Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021;6(1):I–LXII. doi:10.1177/2396987321989865
   PubMed Web of Science ®Google Scholar
• Schell M, Thomalla G. Intravenöse Lyse-Therapie beim ischämischen Schlaganfall–Schritt für Schritt. [Intravenous lysis therapy in ischemic stroke - step by step]. Neurologie up2date. 2020;3(4):329–336. German. doi:10.1055/a-1163-4712
   Google Scholar
• Leitfaden der Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). “Orale Antikoagulation bei nicht valvulärem Vorhofflimmern”[Guidelines of the Drug Commission of the German Medical Association “Oral anticoagulation in non-valvular atrial fibrillation”]. Empfehlungen zum Einsatz der direkten oralen Antikoagulanzien Dabigatran (Pradaxa^®), Apixaban (Eliquis^®), Edoxaban (Lixiana^®) und Rivaroxaban (Xarelto^®). [Recommendations for the use of the direct oral anticoagulants dabigatran (Pradaxa^®), apixaban (Eliquis^®), edoxaban (Lixiana^®) and Rivaroxaban (Xarelto^®)]; 2019. German.
   Google Scholar
• Smits E, Andreotti F, Houben E, et al. Adherence and persistence with once-daily vs twice-daily direct oral anticoagulants among patients with atrial fibrillation: real-world analyses from the Netherlands, Italy and Germany. Drugs Real World Outcomes. 2022; 2022:1–11. doi:10.1007/s40801-021-00289-w
   Google Scholar